The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma:
a judicious option?
To access this article, please choose from the options below
PII: S0959-8049(03)00927-4
doi:10.1016/j.ejca.2003.09.035
© 2003 Elsevier Science Ltd. All rights reserved.
